Jing-Yi Chen, Ying-Tzu Chang, Yu-Cheng Ho, Yu-Ning Teng
{"title":"艾利索三萜在细胞膜上表现出三重调节机制以克服癌症多药耐药。","authors":"Jing-Yi Chen, Ying-Tzu Chang, Yu-Cheng Ho, Yu-Ning Teng","doi":"10.2147/DDDT.S521116","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose and study design: </strong>Multi-drug resistance (MDR) in cancer significantly hinders effective treatment, leading to poor patient outcomes. The study investigates the potential of natural compounds, Alisol B 23-acetate (B23) and Alisol A 24-acetate (A24), to reverse MDR through various mechanisms on cancer cell membranes.</p><p><strong>Results: </strong>Cytotoxicity assays established non-toxic concentrations of B23 and A24, which were then tested in drug-sensitive and drug-resistant cancer cell lines with or without chemotherapeutic drugs. Both compounds significantly enhanced reactive oxygen species (ROS) production and apoptosis in HepG2/VIN MDR cells while preserving cell membrane integrity. They also improved membrane fluidity and inhibited the function of P-glycoprotein (P-gp) efflux transporters in both HepG2/VIN and <i>ABCB1</i>/Flp-In<sup>TM</sup>-293, leading to increased drug accumulation. Molecular docking studies revealed that B23 and A24 interact with distinct binding sites on P-gp, demonstrating allosteric and competitive inhibition.</p><p><strong>Conclusion: </strong>B23 and A24 effectively reverse cancer MDR by (1) modulating ROS levels and inducing apoptosis, (2) maintaining membrane integrity but improving membrane fluidity, and (3) inhibiting drug efflux by membrane transporters. These findings provide a promising basis for developing new therapeutic strategies to combat MDR in cancer, highlighting the potential use of these natural product derivatives in adjunctive cancer therapy.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"5471-5488"},"PeriodicalIF":4.7000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208304/pdf/","citationCount":"0","resultStr":"{\"title\":\"Alisol Triterpenoids Exhibit Triple Modulatory Mechanisms on the Cell Membrane to Overcome Cancer Multidrug Resistance.\",\"authors\":\"Jing-Yi Chen, Ying-Tzu Chang, Yu-Cheng Ho, Yu-Ning Teng\",\"doi\":\"10.2147/DDDT.S521116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose and study design: </strong>Multi-drug resistance (MDR) in cancer significantly hinders effective treatment, leading to poor patient outcomes. The study investigates the potential of natural compounds, Alisol B 23-acetate (B23) and Alisol A 24-acetate (A24), to reverse MDR through various mechanisms on cancer cell membranes.</p><p><strong>Results: </strong>Cytotoxicity assays established non-toxic concentrations of B23 and A24, which were then tested in drug-sensitive and drug-resistant cancer cell lines with or without chemotherapeutic drugs. Both compounds significantly enhanced reactive oxygen species (ROS) production and apoptosis in HepG2/VIN MDR cells while preserving cell membrane integrity. They also improved membrane fluidity and inhibited the function of P-glycoprotein (P-gp) efflux transporters in both HepG2/VIN and <i>ABCB1</i>/Flp-In<sup>TM</sup>-293, leading to increased drug accumulation. Molecular docking studies revealed that B23 and A24 interact with distinct binding sites on P-gp, demonstrating allosteric and competitive inhibition.</p><p><strong>Conclusion: </strong>B23 and A24 effectively reverse cancer MDR by (1) modulating ROS levels and inducing apoptosis, (2) maintaining membrane integrity but improving membrane fluidity, and (3) inhibiting drug efflux by membrane transporters. These findings provide a promising basis for developing new therapeutic strategies to combat MDR in cancer, highlighting the potential use of these natural product derivatives in adjunctive cancer therapy.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"5471-5488\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208304/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S521116\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S521116","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Alisol Triterpenoids Exhibit Triple Modulatory Mechanisms on the Cell Membrane to Overcome Cancer Multidrug Resistance.
Purpose and study design: Multi-drug resistance (MDR) in cancer significantly hinders effective treatment, leading to poor patient outcomes. The study investigates the potential of natural compounds, Alisol B 23-acetate (B23) and Alisol A 24-acetate (A24), to reverse MDR through various mechanisms on cancer cell membranes.
Results: Cytotoxicity assays established non-toxic concentrations of B23 and A24, which were then tested in drug-sensitive and drug-resistant cancer cell lines with or without chemotherapeutic drugs. Both compounds significantly enhanced reactive oxygen species (ROS) production and apoptosis in HepG2/VIN MDR cells while preserving cell membrane integrity. They also improved membrane fluidity and inhibited the function of P-glycoprotein (P-gp) efflux transporters in both HepG2/VIN and ABCB1/Flp-InTM-293, leading to increased drug accumulation. Molecular docking studies revealed that B23 and A24 interact with distinct binding sites on P-gp, demonstrating allosteric and competitive inhibition.
Conclusion: B23 and A24 effectively reverse cancer MDR by (1) modulating ROS levels and inducing apoptosis, (2) maintaining membrane integrity but improving membrane fluidity, and (3) inhibiting drug efflux by membrane transporters. These findings provide a promising basis for developing new therapeutic strategies to combat MDR in cancer, highlighting the potential use of these natural product derivatives in adjunctive cancer therapy.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.